Preparation and in vitro evaluation of hemoglobin-paclitaxel dual loaded liposomes for improving tumor hypoxia resistance
10.13303/j.cjbt.issn.1004549x.2024.03.007
- VernacularTitle:改善肿瘤缺氧耐药的血红蛋白-紫杉醇脂质体的制备及体外评价
- Author:
Xunyi YOU
1
;
Kehui ZHU
2
;
Jing XIAO
1
;
Jiakang WU
1
;
Shifan ZHENG
1
;
Along ZHANG
1
;
Rui ZHONG
1
;
Hong WANG
1
;
Ye CAO
1
;
Jiaxin LIU
1
Author Information
1. Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu 610052, China
2. Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China
- Publication Type:Journal Article
- Keywords:
hemoglobin;
liposome;
paclitaxel;
tumor;
hypoxia
- From:
Chinese Journal of Blood Transfusion
2024;37(3):297-303
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To prepare liposomes encapsulate hemoglobin and paclitaxel(LEHP)to improve tumor hypoxia resistance. 【Methods】 LEHP were prepared by thin-film method, and the particle size, Zeta potential and polydispersity were investigated by nanoparticle size analyzer, and encapsulation efficiency was investigated by high performance liquid chromatography, and the interaction between the liposomes and tumor cells was evaluated by in vitro cell experiments. 【Results】 The optimal preparation conditions of LEHP was as follows: total phospholipid 36 mM, DPPC∶Dope∶cholesterol molar ratio 7∶2∶1, paclitaxel 3 mg, hydrated with 3 mg·mL-1 Hb-PBS for 30 min at room temperature; The average particle size was (189.17±8.22) nm, polydispersity was 0.14±0.023, paclitaxel encapsulation efficiency was (58.27±2.55)%, hemoglobin content was (0.63±0.05) mg·mL-1. In vitro cell experiments, the killing effect of LEHP was about 1.5 times that of LEP, about 1.2 times that of LEP, and ROS production was about 1.8 times that of LEP. 【Conclusion】 The preparation conditions of LEHP was optimized, and cell experiments showed that LEHP can promote tumor cell apoptosis by improving hypoxia and increasing ROS production, which is expected to provide a safe and effective new method for drug resistance caused by tumor hypoxia.
